Group 1 - The stock of Beihai Kangcheng-B (01228) has surged over 9%, with a remarkable year-to-date increase of 16 times, currently trading at 2.4 HKD with a transaction volume of 16.13 million HKD [1] - In the first half of the year, Beihai Kangcheng reported revenues of 22.248 million HKD, a decrease of 50.33% year-on-year, while achieving a profit of 59.238 million HKD, compared to a loss of 247 million HKD in the same period last year [1] - The revenue decline is attributed to the company's strategic focus on rare diseases since 2021, with the termination of the distribution agreement for the product He Li An in Taiwan by the end of 2024, leading to a 170,000 HKD or 6.9% decrease in revenue excluding sales in Taiwan [1] Group 2 - In August, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million HKD to acquire shares in Beihai Kangcheng [2] - The agreement includes a commercial service contract that grants Baiyang's subsidiary promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [2] - Beihai Kangcheng's three rare disease products have passed the preliminary review for the commercial insurance innovative drug directory announced by the National Healthcare Security Administration, including the recently approved long-term enzyme replacement product for Gaucher disease patients [2]

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in its stock price, rising over 12% recently and nearly 20 times year-to-date, indicating strong market interest and potential growth opportunities [1] Group 1: Stock Performance - As of the latest update, Beihai Kangcheng's stock price is reported at 2.77 HKD, with a trading volume of 50.08 million HKD [1] - The stock has experienced a year-to-date increase of nearly 2000% [1] Group 2: Strategic Partnerships - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, with Baiyang investing 100 million HKD in Beihai Kangcheng [1] - The partnership includes a commercial service agreement, allowing Baiyang's subsidiary to promote specific products from Beihai Kangcheng in mainland China, Hong Kong, and Macau [1] Group 3: Regulatory Developments - In 2025, the National Healthcare Security Administration will introduce a "Commercial Insurance Innovative Drug Directory," with application processes starting on July 11 [1] - Three of Beihai Kangcheng's products have passed the initial review as of August 12, which could expedite their market entry [1] - Inclusion in the Commercial Insurance Innovative Drug Directory would provide commercial insurance support for these drugs, potentially reducing the economic burden on patients and increasing product accessibility [1]

Group 1 - Beihai Kangcheng-B (01228) has seen a nearly 17% increase recently, with a year-to-date cumulative increase exceeding 1500% [1] - As of the report, the stock price is at 2.23 HKD, with a trading volume of 41.075 million HKD [1] - Beihai Kangcheng has entered into a share subscription agreement with Baiyang Pharmaceutical (301015), where Baiyang will subscribe for shares worth approximately 100 million HKD at a price of 1.34 HKD per share [1] Group 2 - The two companies have signed an exclusive commercialization service agreement to deepen strategic collaboration, allowing Baiyang's subsidiary to promote specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1] - On August 12, the National Healthcare Security Administration released the preliminary list of innovative drugs for commercial insurance, with three rare disease products from Beihai Kangcheng passing the review [1] - The approved products include: - Gorynin (injectable velaglucerase beta) for long-term enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease - Mairuibai (oral chloramphenicol) for treating ALGS/PFIC cholestatic pruritus - Haierisi (injectable idursulfase beta) for treating Mucopolysaccharidosis Type II [1]

北海康成-B(01228)再涨近9%，截至发稿，涨3.47%，报2.09港元，成交额2027.73万港元。 此外，北海康成近日公布，向百洋医药（301015）(301015.SZ)发行7497万股新股，每股作价1.34港元， 较停牌前收报折让19.76%，认购事项所得款项净额约9866.18万港元，拟用于商业化产品的研发；营销 及推广活动；偿还贷款融资；及日常营运。完成后，百洋医药将持有公司股本14.99%，后者已表示其 无意于三年内收购公司任何控股股份。 消息面上，国家医保局8月12日公布商保创新药目录初审名单。北海康成三款罕见病产品均通过了商保 创新药目录的形式审查。包括今年5月获批上市的用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的 长期酶替代产品戈芮宁(注射用维拉苷酶β)；用于治疗ALGS/PFIC胆汁淤积性瘙痒的迈芮倍(氯马昔巴特 口服液)；用于治疗黏多糖贮积症II型的海芮思(艾度硫酸酯酶β注射液)。 ...